Biotechnology · South San Francisco, California, United States
n/a
Smart-Money SignalNeutral · 44/100— Insider open-market flow is flat over 90 days
Net Income-$14.5M
EPS$-1.99
Price Performance
Historical data including institutional events
Company Profile
C
Christopher Kirk
CEO & Executive Director
Kezar Life Sciences, Inc., a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases in the United States. The companyâs lead product candidate is zetomipzomib (KZR-616), a selective immunoproteasome inhibitor for various indications, including lupus nephritis, dermatomyositis, and polymyositis; and Phase 1b/2 clinical trials in systemic lupus erythematosus. It is also developing KZR-261, a novel first-in-class protein secretion inhibitor for the treatment of tumors resistant to traditional chemotherapeutics. Kezar Life Sciences, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.
- Founded
- 2015
- Employees
- 55
- Headquarters
- South San Francisco, California, United States
- Website
- www.kezarlifesciences.com
Peer ComparisonRevenue ($B)
▾Loading company sections...